Cytokine release syndrome treated with tocilizumab following ipilimumab–nivolumab combination therapy in advanced renal cell carcinoma
This case highlights the importance of increased awareness, prompt recognition, and targeted management of cytokine release syndrome in renal cell carcinoma patients receiving immune checkpoint inhibitor combination therapy. The rapid response to tocilizumab suggests its potential efficacy in managing immune checkpoint inhibitor-induced cytokine release syndrome.
Authors
- Toshitaka Shin (ORCID: https://orcid.org/0000-0001-7015-4281)
- Akiko Todaka (ORCID: https://orcid.org/0000-0002-7308-5960)
- Shinya Sejiyama
- Masahiro Fuse
- Tadasuke Ando (ORCID: https://orcid.org/0000-0003-1470-6517)
- Toru Inoue (ORCID: https://orcid.org/0000-0002-8290-0322)
- Shuntaro Suzuki
Institutions
- Oita University (JP)
Publication Details
- Journal
- IJU Case Reports
- Published
- 2024-11-29
- DOI
- https://doi.org/10.1002/iju5.12812
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.28